Literature DB >> 3605787

Murine/bovine hybridomas producing monoclonal alloantibodies to bovine red cell antigens.

E M Tucker, S W Clarke, L Méténier.   

Abstract

In attempts to produce stable lines secreting bovine monoclonal antibodies, murine/bovine hybridomas (1 degree xenohybridomas) were selectively cultured in 8-azaguanine to derive HAT-sensitive lines that were then used as myeloma partners for further fusions with bovine lymphocytes. The resulting 2 degrees xenohybridomas were further selected to produce 3 degrees xenohybridomas. Four stable lines secreting bovine monoclonal antibodies recognizing blood group determinants X1 (an IgG1), E'2 (an IgM) and SU" (an IgGI) and another (an IgGI) as yet unidentified were produced from fusions of 2 degrees xenohybridomas with lymphocytes from calves that had been immunized with bovine red cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3605787     DOI: 10.1111/j.1365-2052.1987.tb00741.x

Source DB:  PubMed          Journal:  Anim Genet        ISSN: 0268-9146            Impact factor:   3.169


  4 in total

1.  A bovine monoclonal antibody to oestrone/oestradiol prepared by a (murine x bovine) xbovine interspecies fusion.

Authors:  D J Groves; J Clayton; B A Morris
Journal:  Vet Immunol Immunopathol       Date:  1988-02       Impact factor: 2.046

Review 2.  The production and application of non-rodent monoclonal antibodies in veterinary science.

Authors:  D J Groves; E M Tucker
Journal:  Vet Immunol Immunopathol       Date:  1989-11-30       Impact factor: 2.046

3.  Construction of a bovine-murine heteromyeloma cell line; production of bovine monoclonal antibodies against rotavirus and pregnant mare serum gonadotrophin.

Authors:  P Booman; M Tieman; D Van Zaane; A A Bosma; G F De Boer
Journal:  Vet Immunol Immunopathol       Date:  1990-03       Impact factor: 2.046

4.  Optimization of culture conditions for feline x murine heterohybridomas.

Authors:  E Leidinger; E Kramberger-Kaplan; M Gemeiner
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1993-10       Impact factor: 2.268

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.